"This marks Galderma's eighth FDA aesthetics approval in 5 years, illustrating our long-term commitment to advancing aesthetics through new innovation," said Alisa Lask, general manager and vice president of the U.S. Aesthetics Business at Galderma. "The chin is the foundational anchor of the face that brings the rest of your features into balance. Consumers can now address the chin with a non-surgical, safe option from a brand that uses cutting-edge XpresHAn Technology to shape and produce long-lasting results." Results of a pivotal Phase 3 clinical trial showed that 74% of the patients experienced significantly improved chin projection for up to 1 year as measured by the Galderma Chin Retrusion Scale (GCRS), and 86% of patients, when asked at 12 weeks. Positive aesthetic outcomes following treatment were demonstrated through high levels of subject satisfaction in FACE-Q, and Global Aesthetic Improvement Scale (GAIS) questionnaires.